Trousseau Syndrome — SCE Medical Oncology MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: C — Cancer-associated hypercoagulability from tumour-derived procoagulant factors (tissue factor
Trousseau syndrome (migratory superficial thrombophlebitis, often nonbacterial thrombotic endocarditis) is a classic paraneoplastic manifestation of cancer-associated hypercoagulability. Mechanisms: tumour-derived tissue factor expression, cancer procoagulant (cysteine protease), mucin-mediated platelet aggregation (especially mucin-secreting adenocarcinomas — pancreatic, gastric, ovarian, lung). It can precede cancer diagnosis by months. LMWH is the preferred anticoagulant (warfarin is often ineffective in Trousseau syndrome due to the non-warfarin-sensitive coagulation pathway activation).
Reference: https://www.nice.org.uk/guidance/conditions-and-diseases/cancer